ALOX5 and B-cell chronic lymphocytic leukemia: We conclude that there is heterogeneity in the sensitivity of the different CLL samples to the drugs tested, and the effects of the 5-LOX pathway inhibitors resemble each other to a greater extent than to ibrutinib.